# SANTA CRUZ BIOTECHNOLOGY, INC.

# cyclin D3 (18B6-10): sc-453



## BACKGROUND

The proliferation of eukaryotic cells is controlled at specific points in the cell cycle, particularly at the G<sub>1</sub> to S and the G<sub>2</sub> to M transitions. It is well established that the Cdc2 p34-cyclin B protein kinase plays a critical role in the G<sub>2</sub> to M transition while cyclin A associates with Cdk2 p33 and functions in S phase. Considerable effort directed towards the identification of G<sub>1</sub> cyclins has led to the isolation of cyclin D, cyclin C and cyclin E. Of these, cyclin D corresponds to a putative human oncogene, designated PRAD1, which maps at the site of the Bcl-1 rearrangement in certain lymphomas and leukemias. Two additional human type D cyclins, as well as their mouse homologs, have been identified. Evidence has established that members of the cyclin D family function to regulate phosphorylation of the retinoblastoma gene product, thereby activating E2F transcription factors.

## CHROMOSOMAL LOCATION

Genetic locus: CCND3 (human) mapping to 6p21.1; Ccnd3 (mouse) mapping to 17 C.

#### SOURCE

cyclin D3 (18B6-10) is a rat monoclonal antibody raised against recombinant cyclin D3 protein of mouse origin.

#### PRODUCT

Each vial contains 200  $\mu g~lg G_{2a}$  in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

cyclin D3 (18B6-10) is available conjugated to agarose (sc-453 AC), 500 µg/ 0.25 ml agarose in 1 ml, for IP; to HRP (sc-453 HRP), 200 µg/ml, for WB, IHC(P) and ELISA; to either phycoerythrin (sc-453 PE), fluorescein (sc-453 FITC), Alexa Fluor<sup>®</sup> 488 (sc-453 AF488), Alexa Fluor<sup>®</sup> 546 (sc-453 AF546), Alexa Fluor<sup>®</sup> 594 (sc-453 AF594) or Alexa Fluor<sup>®</sup> 647 (sc-453 AF647), 200 µg/ml, for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor<sup>®</sup> 680 (sc-453 AF680) or Alexa Fluor<sup>®</sup> 790 (sc-453 AF790), 200 µg/ml, for Near-Infrared (NIR) WB, IF and FCM.

Alexa Fluor® is a trademark of Molecular Probes, Inc., Oregon, USA

#### **APPLICATIONS**

cyclin D3 (18B6-10) is recommended for detection of cyclin D3 p34 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and immunohistochemistry (including paraffinembedded sections) (starting dilution 1:50, dilution range 1:50-1:500).

Suitable for use as control antibody for cyclin D3 siRNA (h): sc-35136, cyclin D3 siRNA (m): sc-35137, cyclin D3 shRNA Plasmid (h): sc-35136-SH, cyclin D3 shRNA Plasmid (m): sc-35137-SH, cyclin D3 shRNA (h) Lentiviral Particles: sc-35136-V and cyclin D3 shRNA (m) Lentiviral Particles: sc-35137-V.

Molecular Weight of cyclin D3: 33 kDa.

Positive controls: Jurkat nuclear extract: sc-2132, Jurkat + PMA nuclear extract: sc-2133 or K-562 whole cell lysate: sc-2203.

## STORAGE

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## DATA





goat anti-rat IgG-HRP: sc-2065. Western blot analysis of cyclin D3 expression in PMA induced Jurkat nuclear extract. Antibody tested: cyclin D3 (18B6-10): sc-453. cyclin D3 (1886-10): sc-453. Immunoperoxidase staining of formalin fixed, paraffin-embedded human pancreas tissue showing nuclear staining of exocrine glandular cells.

## SELECT PRODUCT CITATIONS

- Kranenburg, O., et al. 1995. Inhibition of cyclin-dependent kinase activity triggers neuronal differentiation of mouse neuroblastoma cells. J. Cell Biol. 131: 227-234.
- 2. Glassford, J., et al. 2003. BCR targets cyclin D2 via Btk and the p85 $\alpha$  subunit of PI3-K to induce cell cycle progression in primary mouse B cells. Oncogene 22: 2248-2259.
- Glassford, J., et al. 2005. Phosphatidylinositol 3-kinase is required for the transcriptional activation of cyclin D2 in Bcr activated primary mouse B lymphocytes. Eur. J. Immunol. 35: 2748-2761.
- 4. Soeiro, I., et al. 2006. p27 Kip1 and p130 cooperate to regulate hematopoietic cell proliferation *in vivo*. Mol. Cell. Biol. 26: 6170-6184.
- 5. Filipczyk, A.A., et al. 2007. Differentiation is coupled to changes in the cell cycle regulatory apparatus of human embryonic stem cells. Stem Cell Res. 1: 45-60.
- Shi, M.D., et al. 2008. Inhibition of cell-cycle progression in human colorectal carcinoma Lovo cells by andrographolide. Chem. Biol. Interact. 174: 201-210.
- Selma Dagtas, A. and Gilbert, K.M. 2010. p21<sup>Cip1</sup> up-regulated during histone deacetylase inhibitor-induced CD4+ T-cell anergy selectively associates with mitogen-activated protein kinases. Immunology 129: 589-599.
- 8. O'Hara, J., et al. 2012. AlB1:ER $\alpha$  transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells. Clin. Cancer Res. 18: 3305-3315.
- Díaz-López, I., et al. 2019. An mRNA-binding channel in the ES6S region of the translation 48S-PIC promotes RNA unwinding and scanning. Elife 8: e48246.

# **RESEARCH USE**

For research use only, not for use in diagnostic procedures.